Science Explorer Back to mapMap
Discussion
Company · Doylestown · United States

ImCare Biotech (United States)

imcarebiotech.comROR OpenAlex
Research works
4
▲ 3511% vs 2018-21
Citations
9
2.5 per fractional work
Top-10% rate
6.8%
all institutions 10.0%
Open access
58%
world 40%
International
10%
world 18%
ImCare Biotech (United States)

Not ranked overall: ImCare Biotech (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does ImCare Biotech (United States) work in?

In all years, 75% of research at ImCare Biotech (United States) is in Health Sciences, 14% in Life Sciences. Its largest fields are Medicine (69%), Biochemistry, Genetics and Molecular Biology (14%), Computer Science (6%). It does 1.5× the world's share of Health Sciences.

Health Sciences: 3 fractional works · 75.0% of its workMedicine: 2 fractional works · 69.4% of its workHealth Professions: 0 fractional works · 5.6% of its workLife Sciences: 0 fractional works · 13.9% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 13.9% of its workPhysical Sciences: 0 fractional works · 5.6% of its workComputer Science: 0 fractional works · 5.6% of its workSocial Sciences: 0 fractional works · 5.6% of its workDecision Sciences: 0 fractional works · 5.6% of its workALL ITS WORKImCare Biotech(United States)4fractional works, all years
Life Sciences14%Physical Sciences6%Health Sciences75%Social Sciences6%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 5 fields, with their numbers
    1. Medicine269.4%
    2. Health Professions05.6%
    1. Biochemistry, Genetics and Molecular Biology013.9%
    1. Computer Science05.6%
    1. Decision Sciences05.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from ImCare Biotech (United States)?

The most cited paper from ImCare Biotech (United States) is "ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation" (Hui Yuwen, Huajing Wang, Tengteng Li et al., 2024), with 20 citations. Next come "Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system" (16) and "Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma" (14).

Most cited papers
#PaperReleasedCitations
1 ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation Hui Yuwen, Huajing Wang, Tengteng Li et al. · Cancer Research Open access 19 Mar 2024 20
2 Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system Jason Lamontagne, Courtney Mills, Richeng Mao et al. · Antiviral Research Open access 13 Feb 2013 16
3 Liver Cancer–Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma Felix Lu et al. · Clinical and Translational Gastroenterology Open access 23 Nov 2020 14
4 The experiences of people starting haemodialysis: A qualitative study Kshama Mehta, Wael F. Hussein, Kerstin K. Leuther et al. · Journal of Renal Care Open access 11 May 2024 4
5 Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC) Felix Lu, Connor Ott, Prabha K. Bista et al. · Diagnostics Open access 29 Mar 2024 1
All 6 most cited papers, with filters and sorting

Which research topics does ImCare Biotech (United States) publish most on?

By volume in 2022-now: Cancer Research and Treatments, Cancer Immunotherapy and Biomarkers, Liver Disease Diagnosis and Treatment and Hepatitis C virus research.

Cancer Research and Treatments: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksLiver Disease Diagnosis …0Liver Disease Diagnosis and Treatment: 0 fractional worksHepatitis C virus research0Hepatitis C virus research: 0 fractional worksHepatocellular Carcinoma Treatment and Prognosis: 0 fractional worksLymphoma Diagnosis and Treatment: 0 fractional worksMetastasis and carcinoma…0Metastasis and carcinoma case studies: 0 fractional worksScientific Computing and Data Management: 0 fractional worksArtificial Intelligence in Healthcare: 0 fractional worksHER2/EGFR in Cancer Rese…0HER2/EGFR in Cancer Research: 0 fractional works
BiotechnologyOncologyEpidemiologyHepatology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Cancer Research and Treatments Biotechnology 0 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 0 works
  3. 3 Liver Disease Diagnosis and Treatment Epidemiology 0 works
  4. 4 Hepatitis C virus research Hepatology 0 works
  5. 5 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 0 works
  6. 6 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  7. 7 Metastasis and carcinoma case studies Pulmonary and Respiratory Medicine 0 works
  8. 8 Scientific Computing and Data Management Information Systems and Management 0 works
  9. 9 Artificial Intelligence in Healthcare Health Information Management 0 works
  10. 10 HER2/EGFR in Cancer Research Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available58.3%not open41.7%

World: 40% of research is openly available.

with international co-authors9.5%domestic only90.5%

World: 18% is written across borders.

How has ImCare Biotech (United States)'s research output changed?

Output in 2022-2025 was 3511% higher than in 2018-2021.

still counting201520202025

Other research institutions in Doylestown

All research institutions in Doylestown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about ImCare Biotech (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.